Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 762,100 | 2,342,100 | 1,572,000 | 720,100 | 653,100 |
| Depreciation Amortization | 35,900 | 125,600 | 91,800 | 60,100 | 28,800 |
| Income taxes - deferred | -12,300 | -154,600 | -112,700 | -180,900 | 57,000 |
| Accounts receivable | -165,200 | -274,700 | -231,200 | -45,900 | -98,400 |
| Accounts payable and accrued liabilities | -14,500 | 31,900 | -22,000 | -24,300 | -10,600 |
| Other Working Capital | -32,800 | -105,200 | -239,800 | -148,400 | 16,200 |
| Other Operating Activity | 383,000 | 678,400 | 590,400 | 340,600 | 274,900 |
| Operating Cash Flow | $956,200 | $2,643,500 | $1,648,500 | $721,300 | $921,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -63,600 | -235,000 | -173,200 | -120,800 | -70,900 |
| Purchase Of Investment | -117,100 | -605,200 | -485,800 | -254,500 | -121,500 |
| Sale Of Investment | 129,700 | 499,300 | 452,100 | 221,300 | 118,100 |
| Investing Cash Flow | $-51,000 | $-340,900 | $-206,900 | $-154,000 | $-74,300 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 28,300 | 12,600 | 11,600 | 3,600 |
| Debt Repayment | -12,900 | -47,000 | -34,600 | -22,500 | -12,200 |
| Common Stock Issued | 33,700 | 102,000 | 67,300 | 53,500 | 15,600 |
| Common Stock Repurchased | 0 | -1,425,400 | -1,057,200 | -424,900 | -424,900 |
| Other Financing Activity | -116,200 | -135,900 | -129,900 | -102,800 | -100,800 |
| Financing Cash Flow | $-95,400 | $-1,478,000 | $-1,141,800 | $-485,100 | $-518,700 |
| Exchange Rate Effect | -5,900 | -13,400 | -8,500 | 0 | -4,000 |
| Beginning Cash Position | 6,800,100 | 5,988,900 | 5,988,900 | 5,988,900 | 5,988,900 |
| End Cash Position | 7,604,000 | 6,800,100 | 6,280,200 | 6,071,100 | 6,312,900 |
| Net Cash Flow | $803,900 | $811,200 | $291,300 | $82,200 | $324,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 956,200 | 2,643,500 | 1,648,500 | 721,300 | 921,000 |
| Capital Expenditure | -63,600 | -235,000 | -173,200 | -120,800 | -70,900 |
| Free Cash Flow | 892,600 | 2,408,500 | 1,475,300 | 600,500 | 850,100 |